HHS Public Access Author manuscript Author Manuscript
Ann Surg. Author manuscript; available in PMC 2017 October 01. Published in final edited form as: Ann Surg. 2016 October ; 264(4): 575–584. doi:10.1097/SLA.0000000000001873.
A Highly Predictive Model for Diagnosis of Colorectal Neoplasms Using Plasma MicroRNA: Improving Specificity and Sensitivity
Author Manuscript
Jane V. Carter, MB ChB*, Henry L. Roberts, BS*, Jianmin Pan, Ph.D†, Jonathan D. Rice, M.D*, James F. Burton, BA*, Norman J. Galbraith, MB ChB*, M. Robert Eichenberger, MS*, Jeffery Jorden, M.D*, Peter Deveaux, M.D*, Russell Farmer, M.D*, Anna Williford, BSN*, Ziad Kanaan, M.D Ph.D††, Shesh N. Rai, Ph.D§,†, and Susan Galandiuk, M.D* *Price
Institute of Surgical Research, Section of Colorectal Surgery, Hiram C. Polk Jr M.D Department of Surgery, University of Louisville School of Medicine, Louisville, KY
†Department
of Bioinformatics and Biostatistics, University of Louisville School of Medicine, Louisville, KY
§Biostatistics
Shared Facility, James Graham Brown Cancer Center, University of Louisville, KY
††Department
of Internal Medicine, Department of Gastroenterology, Wayne State University, the Detroit Medical Center, Detroit, MI
Abstract Author Manuscript
OBJECTIVE(S)—Develop a plasma-based microRNA (miRNA) diagnostic assay specific for colorectal neoplasms, building upon our prior work. BACKGROUND—Colorectal neoplasms (colorectal cancer [CRC] and colorectal advanced adenoma [CAA]) frequently develop in individuals at ages when other common cancers also occur. Current screening methods lack sensitivity, specificity, and have poor patient compliance.
Author Manuscript
METHODS—Plasma was screened for 380 miRNAs using microfluidic array technology from a “Training” cohort of 60 patients, (10 each) control, CRC, CAA, breast (BC), pancreatic (PC) and lung (LC) cancer. We identified uniquely dysregulated miRNAs specific for colorectal neoplasia (p
Ann Surg. Author manuscript; available in PMC 2017 October 01. Published in final edited form as: Ann Surg. 2016 October ; 264(4): 575–584. doi:10.1097/SLA.0000000000001873.
A Highly Predictive Model for Diagnosis of Colorectal Neoplasms Using Plasma MicroRNA: Improving Specificity and Sensitivity
Author Manuscript
Jane V. Carter, MB ChB*, Henry L. Roberts, BS*, Jianmin Pan, Ph.D†, Jonathan D. Rice, M.D*, James F. Burton, BA*, Norman J. Galbraith, MB ChB*, M. Robert Eichenberger, MS*, Jeffery Jorden, M.D*, Peter Deveaux, M.D*, Russell Farmer, M.D*, Anna Williford, BSN*, Ziad Kanaan, M.D Ph.D††, Shesh N. Rai, Ph.D§,†, and Susan Galandiuk, M.D* *Price
Institute of Surgical Research, Section of Colorectal Surgery, Hiram C. Polk Jr M.D Department of Surgery, University of Louisville School of Medicine, Louisville, KY
†Department
of Bioinformatics and Biostatistics, University of Louisville School of Medicine, Louisville, KY
§Biostatistics
Shared Facility, James Graham Brown Cancer Center, University of Louisville, KY
††Department
of Internal Medicine, Department of Gastroenterology, Wayne State University, the Detroit Medical Center, Detroit, MI
Abstract Author Manuscript
OBJECTIVE(S)—Develop a plasma-based microRNA (miRNA) diagnostic assay specific for colorectal neoplasms, building upon our prior work. BACKGROUND—Colorectal neoplasms (colorectal cancer [CRC] and colorectal advanced adenoma [CAA]) frequently develop in individuals at ages when other common cancers also occur. Current screening methods lack sensitivity, specificity, and have poor patient compliance.
Author Manuscript
METHODS—Plasma was screened for 380 miRNAs using microfluidic array technology from a “Training” cohort of 60 patients, (10 each) control, CRC, CAA, breast (BC), pancreatic (PC) and lung (LC) cancer. We identified uniquely dysregulated miRNAs specific for colorectal neoplasia (p
